Boya Bio invests with related party to boost plasma supply

Boya Bio-Pharmaceutical Group (SZSE:300294) announced it will jointly invest with Chengdu Hengna Shun Enterprise Management Consulting to establish Dalate Banner Boya Plasma Collection Co., Ltd. Boya Bio will contribute CNY 4 million, holding 80% equity, while Chengdu Hengna Shun will contribute CNY 1 million for the remaining 20%. The move aims to improve the supply of raw material blood plasma and strengthen the company's market competitiveness. The investment will be funded by Boya Bio's own capital, and will not have a significant adverse impact on the company's financial situation.